

## ABSTRACT

**Purpose:** Clear cell tubulopapillary renal cell carcinoma (CCTPRCC) is a recently described, low grade subtype of renal cancer. We determined if imaging features could be used to distinguish early-stage CCTPRCC from stage-matched clear cell RCC (ccRCC) and papillary RCC (pRCC).

**Subjects and Methods:** This IRB-approved retrospective study included 54 stage-Ia patients with pathologically-confirmed CCTPRCC (n=18), ccRCC (n=18), and pRCC (n=18). CT (n=48) and MRI (n=27) exams were reviewed and imaging features compared. Continuous variables were evaluated using ANOVA and Tukey's multiple comparison tests. Categorical variables were compared using Chi square test or Fisher's exact test.

**Results:** Compared to pRCC, CCTPRCC had a lower mean attenuation value on unenhanced CT ( $p<0.017$ ), was more often hyperintense on T2-weighted images ( $p<0.0001$ ), showed an ill-defined margin ( $p=0.003$ ), and demonstrated nonenhancing areas ( $p=0.0003$ ). The presence of all three of these statistically significant features (hypoattenuation [unenhanced attenuation  $\leq$  25HU], ill-defined margin, nonenhancing areas) yielded an area under the Receiver Operator Curve (ROC) of 0.92 (95% CI: 0.83-0.99) for differentiating CCTPRCC from pRCC. There were no significant differences in the imaging features of CCTPRCC and ccRCC.

**Conclusions:** Early stage clear cell tubulopapillary renal cell carcinoma can be distinguished from papillary RCC based on low attenuation on unenhanced CT, high intensity on T2-weighted images, an ill-defined margin, and presence of nonenhancing areas, but cannot be distinguished from clear cell RCC.

1  
2  
3  
4 **INTRODUCTION**  
5  
6

7 Clear cell tubulopapillary renal cell carcinoma (CCTPRCC) represents a unique subtype of renal  
8 epithelial neoplasm according to the recent International Society of Urological Pathology  
9  
10 Vancouver Classification of Renal Neoplasia [1, 2]. Also known as ‘clear cell papillary renal cell  
11  
12 carcinoma’ and previously referred to as ‘papillary renal cell carcinoma with clear cell features’,  
13  
14 CCTPRCC is now considered the fourth most common variant of RCC, behind ccRCC (70%),  
15  
16 pRCC (16.6%), and chromophobe carcinoma (5.9%), with an incidence of 4.1% [1-6].  
17  
18  
19 CCTPRCC was reported initially in patients with end-stage renal disease, however, the majority  
20  
21 of subsequent cases are now known to occur sporadically [1–3, 5-9]. The average age at  
22  
23 presentation is 60 and there is no sex predilection [1, 2, 8, 9].  
24  
25  
26  
27  
28  
29

30 There is limited literature on the biologic behavior of CCTPRCC, however, prior reports suggest  
31  
32 that these neoplasms behave indolently, and carry a favorable prognosis [1–4, 7-10]. To our  
33  
34 knowledge, metastases have not been reported [1–4, 7-11]. Therefore, the prospective  
35  
36 differentiation of CCTPRCC from the more common subtypes such as clear cell RCC (ccRCC)  
37  
38 and papillary RCC (pRCC) at an early stage may be useful for counseling patients on prognosis  
39  
40 and treatment plans. For example, an active surveillance approach may be considered in a patient  
41  
42 with CCTPRCC [12].  
43  
44  
45  
46  
47

48 To our knowledge, no prior study has attempted to differentiate CCTPRCC from other renal cell  
49  
50 tumor subtypes using imaging features. In a recent study of papillary renal cell carcinoma  
51  
52 subtypes on CT and MRI, CCTPRCC was included as an ‘atypical papillary RCC’ and was not  
53  
54 evaluated as a separate entity [13]. We determined if imaging features could be used to  
55  
56 distinguish early-stage CCTPRCC from stage-matched ccRCC and pRCC.  
57  
58  
59  
60  
61  
62  
63  
64  
65

## SUBJECTS AND METHODS

### *Subjects*

This Health Insurance Portability and Accountability Act-compliant retrospective study was performed after approval of our institutional review board; informed consent was waived. Our pathology database revealed 23 patients with stage Ia CCTPRCC diagnosed at our institution; of these, 20 had a pre-treatment CT scan and/or an MRI examination available for review. Of these 20 patients, two had more than one subtype of RCC (including CCTPRCC) in the same surgical specimen. Therefore, we could not differentiate the two renal cell subtypes on imaging and were excluded. Thus, a total of 18 patients (9 men, 9 women; median age 65 years; range 43-84) with stage Ia CCTPRCC were included in the study. Of these, 11 were examined with both CT and MRI, six with only CT, and one with only MRI. An equivalent number of consecutive stage – matched ccRCC (N=18; 12 men, six women; median age 56 years; range 22-76) and an equivalent number of consecutive stage – matched pRCC (N=18; 10 men, eight women; median age 64 years; range 50-80) were identified and included to comprise a total of 54 patients in the study.

### *CT and MRI Technique*

Of the 54 patients, 27 were examined with CT alone, 21 with both CT and MRI, and six with MRI alone. CT examinations were performed with MDCT scanners (Somatom Volume Zoom, Definition AS 128, Somatom Sensation 64 and 16, all from Siemens Medical Solutions, Erlangen, Germany); or Aquilion 320 and Aquilion 64, both from Toshiba (America Medical Systems, Minnetonka, MN). Images were acquired at 120 kVp and 155–280 mA, and reconstructed at 3- to 5-mm-thick sections in the axial plane and 3-mm thick sections in the

1  
2  
3  
4 coronal plane. Contrast-enhanced CT images were obtained after intravenous injection of 75-120  
5  
6 mL of iopromide (Ultravist 300, Bayer Healthcare, Seattle, WA). Thirty two patients underwent  
7  
8 CT urography, supplemented with the injection of 10 mg of IV furosemide (Lasix, Abbott  
9  
10 Laboratories) administered 2–3 minutes before contrast material, or supplemented with a drip  
11  
12 infusion of 250 mL of IV saline just prior to obtaining the excretory phase images [14]. Nine  
13  
14 patients' CT scans were performed with IV contrast material using a 70s delay without an  
15  
16 unenhanced phase. Seven patients' CT scans were performed without IV or enteric contrast  
17  
18 material administration as part of a CT-guided biopsy planning CT scan. These seven patients'  
19  
20 CT scans were used to assess characteristics that could only be evaluated with unenhanced CT.  
21  
22  
23  
24  
25  
26 MRI examinations were performed on a 1.5-T or 3-T system (Signa Excite 1.5T, GE Healthcare  
27  
28 or Magnetom Verio 3T, Siemens Healthcare). Imaging included an axial fat suppressed T1-  
29  
30 weighted spoiled gradient-echo or a 3D fast-acquisition multiple excitation spoiled gradient-echo  
31  
32 sequence before and after IV gadolinium administration. T2-weighted imaging was performed  
33  
34 with a single-shot fast spin-echo sequence (1,200–2,500/87–92; number of echoes acquired per  
35  
36 TR, 184–264; section thickness, 5 mm; gap, 1 mm; field of view, 32–40 cm) [15]. Respiratory  
37  
38 triggered fat-suppressed single-shot echoplanar diffusion-weighted imaging was performed in  
39  
40 the transverse plane with tri-directional diffusion gradients by using at least three *b* values within  
41  
42 the same acquisition. Of the 27 patients who were examined with MRI, two did not receive IV  
43  
44 contrast material due to impaired renal function.  
45  
46  
47  
48  
49  
50

### 51 52 *Assessment of Imaging Features on Both CT and MRI*

53  
54

55 Index CT and MRI exams were assessed independently by three abdominal radiologists with  
56  
57 five, nine, and 12-years of experience; each was blinded to the pathologic subtype, clinical  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 information, and the scores of the other readers. Discrepancies were resolved in consensus. The  
5  
6 following imaging features were recorded for all tumors: maximal tumor diameter (mm), tumor  
7  
8 location (upper pole, mid kidney, or lower pole), growth pattern (endophytic, <50% exophytic or  
9  
10  $\geq 50\%$  exophytic), tumor margin (well-defined or ill-defined), tumor composition (solid or  
11  
12 cystic), appearance on unenhanced, nephrographic, and excretory phase CT, attenuation values  
13  
14 (HU) on all three phases, signal intensity on T1 (hypo-, iso-, hyperintense to renal parenchyma),  
15  
16 T2 appearance (hypo-, iso-, hyperintense to renal parenchyma), appearance on diffusion  
17  
18 weighted images (hypo-, iso-, hyperintense to renal parenchyma), as well as the presence or  
19  
20 absence of calcification, central scar, capsule, nonenhancing areas, lesional fat, and lesional  
21  
22 hemosiderin.  
23  
24  
25  
26  
27  
28

29  
30 Maximum tumor diameter was defined as the maximum dimension in the axial plane on  
31  
32 nephrographic or excretory phase images [16]. For growth pattern, a tumor was defined as  
33  
34 endophytic if the tumor was located completely within the renal parenchyma with no bulge of  
35  
36 the capsule [13]. A tumor was considered exophytic if a portion of its margin extended beyond  
37  
38 the edge of the renal parenchyma [13]. A tumor margin was considered to be well-defined if  
39  
40  $>90\%$  of the entire tumor circumference was ‘pencil-thin’ sharp using a narrow window setting  
41  
42 [16]. When both nephrographic and excretory phases were available and there was discordance  
43  
44 between the two, the phase that showed the most well-defined tumor was used. Regarding tumor  
45  
46 composition, a tumor was considered to be cystic when  $\geq 50\%$  of tumor volume was cystic,  
47  
48 defined as fluid attenuation values ( $\leq 20$  HU). Tumors with  $<50\%$  cystic component were  
49  
50 considered to be solid [16].  
51  
52  
53  
54  
55  
56

57 Regions of interest attenuation values were obtained on enhanced CT scans in the portion of the  
58  
59 renal mass that revealed the most enhancement as determined subjectively on the axial images.  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Similar sized regions of interest attenuation values were obtained on the unenhanced CT scans  
5  
6 corresponding to the same area of maximal enhancement. Enhancement was calculated by  
7  
8 subtracting the high-attenuation values of the tumor on unenhanced images from the attenuation  
9  
10 value on each of the following phases: nephrographic and excretory. The maximum degree of  
11  
12 enhancement was recorded. An increase in attenuation of 20 HU or greater indicated  
13  
14 enhancement, an increase of 10-19 HU was considered equivocal, and an increase of less than 10  
15  
16 HU indicated no enhancement [13, 17-19]. For tumors imaged with MRI, the relative signal  
17  
18 intensity in comparison to the normal renal parenchyma (e.g., hypointense, isointense,  
19  
20 hyperintense) was assessed on unenhanced T1, T2, DWI, and contrast-enhanced T1-weighted  
21  
22 images. The presence or absence of enhancement was determined subjectively on subtraction  
23  
24 images.  
25  
26  
27  
28  
29  
30  
31

32 Presence of calcification was assessed only with CT. The presence of a central scar was defined  
33  
34 as a central stellate area of T2 hyperintensity with lack of enhancement during the nephrographic  
35  
36 phase with or without enhancement during subsequent phases [20]. Nonenhancing areas  
37  
38 (assessed for only solid tumors) were defined as hypoattenuating, nonenhancing areas which  
39  
40 were not sharply demarcated and lacked apparent walls. Presence of lesional fat was defined as a  
41  
42 region within the tumor that measured -10HU or less on CT, or exhibited a loss of signal on fat-  
43  
44 saturated T1 images. Presence of intracytoplasmic fat was defined as loss of signal on T1 in- and  
45  
46 out-of-phase imaging. Presence or absence of hemosiderin was only considered for tumors  
47  
48 imaged with MRI and defined as the subjective identification of loss of signal intensity on  
49  
50 longer-TE in-phase images relative to opposed-phase T1-weighted dual-echo gradient-recalled  
51  
52 echo images [13].  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 *Statistical Analysis*  
5  
6

7 Stratified analyses of the three subtypes of RCC were conducted. Categorical variables were  
8 compared using Chi square test (gender, side, tumor location, Fuhrman grade, tumor growth  
9 pattern, capsule, nonenhancing areas, intralesional fat, central scar, presence of hemosiderin,  
10 MRI enhancement, T1, T2, and DWI signal intensities) and Fisher's exact test (tumor margin,  
11 tumor composition, presence of calcification, nephrographic phase appearance,  
12 homogeneity/heterogeneity on T1, T2, and DWI). Continuous variables were evaluated using  
13 ANOVA and Tukey's multiple comparison tests (age, tumor size, mean attenuation on  
14 unenhanced, nephrographic, and excretory phase). Further pairwise analyses were performed for  
15 statistically significant differences. Since three pair-wise analyses were performed, using  
16 Bonferroni correction, a statistically significant value was determined to be  $\leq 0.017$ .  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 Then, the imaging features which were significantly different between the three cancer subtypes  
33 were used to construct a receiver operator curve (ROC) to determine the ability of these features  
34 to be used to differentiate them. The sensitivity and specificity for differentiating them when one  
35 or more of the features were present were calculated also. For this analysis, we assessed the  
36 unenhanced CT attenuation value as a binary variable (whether or not the mass was  
37 hypoattenuating) and performed a threshold analysis using 5 HU increments starting at 20 HU,  
38 and used the lowest attenuation value that yielded a statistically significant difference between  
39 the three cancer subtypes. The number of patients did not allow a multivariate analysis to be  
40 performed. The number of patients also did not allow assessment of signal intensity on T2-  
41 weighted images to be included in the ROC analysis. Statistical analyses were performed using  
42 JMP Pro 11.0.0 (SAS Institute Inc, Cary, NC) and Prism 6 version 6.05 (GraphPad Software Inc,  
43 La Jolla, CA).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## RESULTS

CCTPRCC demonstrated a lower mean attenuation value on unenhanced CT than pRCC (24.9 HU versus 33.7 HU;  $p < 0.017$ ). (Fig. 1). However, the mean attenuation value of CCTPRCC (24.9 HU) was not different from that of ccRCC (25.9 HU) ( $p > 0.05$ ) (Table 1). More CCTPRCCs were T2-hyperintense than pRCC ( $p < 0.0001$ ); similarly more ccRCCs were T2-hyperintense than pRCC ( $p < 0.002$ ) (Fig. 2). However, there was no difference in number of T2-hyperintense CCTPRCCs and ccRCCs ( $p = 0.330$ ). More CCTPRCCs had an ill-defined margin than pRCC ( $p = 0.003$ ), however, there was no significant difference when compared to ccRCC ( $p = 0.733$ ) (Fig. 3). Of the 54 tumors, 47 were solid. Among these, both CCTPRCC and ccRCC more frequently demonstrated nonenhancing areas than pRCC ( $p = 0.0003$  and  $0.0006$  respectively) (Fig. 4), but there was no difference in the frequency of nonenhancing areas between CCTPRCC and ccRCC ( $p = 0.990$ ).

Several imaging features trended towards statistical significance, but pair-wise analyses did not reveal a statistical significant difference (Table 1). These included appearance of the tumor on nephrographic phase (homogeneous vs heterogeneous,  $p = 0.033$ ), appearance on the T1 unenhanced sequences (homogeneous vs heterogeneous,  $p = 0.045$ ), appearance on the T2 sequences (homogeneous vs heterogeneous,  $p = 0.045$ ), and appearance on the DWI sequences (homogeneous vs heterogeneous,  $p = 0.007$ ). There were no significant differences ( $p > 0.05$ ) between CCTPRCC and the other subtypes for the remaining imaging features (Table 1).

The threshold analysis for attenuation values performed for the purpose of ROC analysis yielded a statistically significant unenhanced attenuation value of  $\leq 25$  HU to differentiate between CCTPRCC and pRCC ( $p = 0.03$ ). An ROC analysis of those features which were significant



1  
2  
3  
4 among the three cancer subtypes demonstrated that the presence of an attenuation value  $\leq 25$  HU,  
5  
6 an ill-defined margin, and the presence of nonenhancing areas could help differentiate  
7  
8 CCTPRCC from pRCC with an area under the curve of 0.92 (95% CI: 0.83-0.99). When at least  
9  
10 one of these features was present, the sensitivity and specificity for diagnosing CCTPRCC was  
11  
12 0.94 and 0.82 respectively. If at least two statistically significant features were present, the  
13  
14 sensitivity and specificity for diagnosing CCTPRCC was 0.47 and 1.0, respectively.  
15  
16  
17  
18

## 19 **DISCUSSION**

20  
21  
22  
23 With the burgeoning role of active surveillance in the management of renal cancer, there is a  
24  
25 growing need for ways to help select which patients need prompt treatment and which do not  
26  
27 [12, 21]. One way to help select patients for active surveillance is to predict their tumors'  
28  
29 biological behavior on the basis of histologic subtype. There are emerging data to suggest that  
30  
31 RCC subtypes may be diagnosed with imaging [22, 23]; however, currently this distinction and  
32  
33 the subsequent clinical management decision often rely on pathology obtained at biopsy.  
34  
35  
36  
37

38 CCTPRCC is a recently recognized subtype of renal cell carcinoma [1, 2] that has gross  
39  
40 morphologic and histologic features which overlap with both ccRCC and pRCC [1-9, 11]. In the  
41  
42 radiology literature, CCTPRCC has been considered among atypical pRCC subtypes [13], and to  
43  
44 our knowledge, the imaging features of this recently described RCC subtype have not been  
45  
46 described. Almost all (>95%) of CCTPRCCs are stage T1a and do not demonstrate local  
47  
48 invasion [1-9, 11]. There are no reported cases of metastases or disease-related deaths [1-11]. In  
49  
50 one study, none of 12 patients with stage T1a or T1b CCTPRCC who were followed (mean 19  
51  
52 months) showed local disease progression or developed a metastasis [4]; a similar favorable  
53  
54 outcome has recently been published in two larger series of CCTPRCC [5, 6]. Therefore, relative  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 to the more common clear cell and papillary subtypes, CCTPRCC is considered an indolent  
5  
6 cancer and may be appropriate to observe rather than treat in selected patients [4, 11].  
7  
8  
9

10 This study suggests that early stage CCTPRCC can be distinguished from pRCC based on a  
11  
12 lower mean attenuation value on unenhanced CT, high signal on T2-weighted images, an ill-  
13  
14 defined margin, and more frequent nonenhancing areas. Specifically, a threshold unenhanced  
15  
16 attenuation of 25 HU was found to be statistically significant for differentiating CCTPRCC from  
17  
18 pRCC. This corroborates earlier works which demonstrated that early stage pRCC is typically  
19  
20 hyperattenuating on unenhanced CT [13, 15]. In contrast, the relatively low attenuation  
21  
22 appearance for CCTPRCC can be explained by its pathology: CCTPRCC can include cystic  
23  
24 components of various sizes [1-3, 7-9]. In fact, in the first description of CCTPRCC, 33 (92%) of  
25  
26  
27 36 tumors included cystic components that often contained serosanguinous fluid or colloid-like  
28  
29 secretions [1].  
30  
31  
32  
33  
34

35 The cystic nature of most of these tumors also probably explains why CCTPRCC were T2-  
36  
37 hyperintense. It is difficult to postulate why CCTPRCC would exhibit an ill-defined margin  
38  
39 relative to pRCC. Perhaps due to their hybrid nature, this feature may mimic ccRCC, which have  
40  
41 been shown to demonstrate ill-defined margins on imaging [16, 17]. The higher frequency of  
42  
43 non-enhancing areas was another feature that could be used to distinguish CCTPRCC from  
44  
45 pRCC. Indeed, 8 (57%) of 14 solid CCTPRCC exhibited nonenhancing areas. This data is  
46  
47 similar to Egbert et al. [13] who described nonenhancing areas in two of six patients with  
48  
49 CCTPRCC. Although others have used non-enhancement in solid masses as an imaging  
50  
51 surrogate for tumor necrosis [16, 17] CCTPRCC typically does not demonstrate necrosis at  
52  
53 histologic evaluation [2, 3]. The nonenhancing areas may represent focal fibrosis, colloid or  
54  
55 glycogen in the cells, focal cystic change, or necrosis [1-3, 5].  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 In practical terms, when encountering a small renal mass, our data allow radiologists to include  
5  
6 CCTPRCC in the differential diagnosis of neoplastic etiologies, and to favor it along with  
7  
8 ccRCC when a mass measures less than or equal to 25 HU, is T2-hyperintense, or exhibits ill-  
9  
10 defined margins, or nonenhancing areas. The presence of two of these features increases the  
11  
12 specificity for differentiating between CCTPRCC and pRCC, but the increased specificity comes  
13  
14 at the cost of lowering the sensitivity. The finding that CCTPRCC cannot be differentiated from  
15  
16 ccRCC is supported by several pathology studies that have described CCTPRCC as a mimicker  
17  
18 of ccRCC [1-3, 11]. For example, pathologists may have difficulty distinguishing CCTPRCC  
19  
20 from ccRCC with a low Fuhrman grade [1, 2, 4], and rely on immunohistochemistry to render  
21  
22 the correct diagnosis [1-4, 7-9, 11, 24].  
23  
24  
25  
26  
27  
28

29  
30 This study had several limitations. The study was retrospective; however, the readers were  
31  
32 blinded to each patient's pathologic diagnosis in order to minimize bias. Also, both CT and MRI  
33  
34 were not available for all patients. However, all patients (except for seven patients whose CT  
35  
36 included only an unenhanced phase) were examined using protocols that included integral  
37  
38 components for renal mass imaging, image acquisitions before and after intravenous contrast  
39  
40 material administration and reconstructions with 3 – 5 mm section thickness [12]. The number of  
41  
42 patients was overall small because the tumor has been only recently described. To our  
43  
44 knowledge, this study is the largest series of CCTPRCC in the radiological literature.  
45  
46  
47  
48

49  
50 In summary, CCTPRCC is a relatively recently described entity that can be included in the  
51  
52 differential diagnosis of renal neoplasms and can be distinguished from pRCC but not ccRCC.  
53  
54 Therefore, since CCTPRCC and ccRCC typically behave differently, more work will be needed  
55  
56 before management decisions such as active surveillance can be made on the basis of imaging  
57  
58 features alone. Additional imaging research may be helpful; for example, IV contrast material  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

dynamics which have been shown to distinguish other renal neoplasm subtypes [22, 23, 25-28] may help distinguish CCTPRCC from ccRCC. Nevertheless, the results of our analysis could serve as the foundation for additional studies on the use of imaging to differentiate the recently described CCTPRCC from other RCC subtypes. Finally, a radiology-pathology correlation study would help understand the pathologic correlates of the imaging features of these sub-types.

1  
2  
3  
4 **REFERENCES**  
5  
6

7  
8 1. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology  
9 (ISUP) Vancouver Classification of Renal Neoplasia. *Am J Surg Pathol* 2013; 37(10):1469–89  
10  
11  
12  
13 2. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36  
14 distinctive low-grade epithelial tumors of the kidney. *Am J Surg Pathol* 2010; 34(11):1608–21  
15  
16  
17  
18 3. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Update on selected  
19 renal cell tumors with clear cell features. With emphasis on multilocular cystic clear cell renal  
20 cell carcinoma. *Histol Histopathol* 2013; 28(12):1555–66  
21  
22  
23  
24 4. Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS. Clear cell papillary renal cell  
25 carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive  
26 nephrectomies for renal cell carcinoma. *Human Pathology* 2014; 45:59-64  
27  
28  
29  
30 5. Aron M, Chang E, Herrera L et al. Clear cell-papillary renal cell carcinoma of the kidney not  
31 associated with end-stage renal disease: clinicopathologic correlation with expanded  
32 immunophenotypic and molecular characterization of a large cohort with emphasis on  
33 relationship with renal angiomyoadenomatous tumor. *Am J Surg Pathol*. 2015; 39:873-88  
34  
35  
36  
37 6. Deml KF, Schildhaus HU, Comperat E et al. Clear cell papillary renal cell carcinoma and  
38 renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and  
39 genetic distinct entity of renal cell carcinoma. *Am J Surg Pathol*. 2015; 39:889-901  
40  
41  
42  
43 7. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct  
44 histopathologic and molecular genetic entity. *Am J Surg Pathol* 2008; 32(8):1239–45  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 8. Adam J, Couturier J, Molinié V, Vieillefond A, Sibony M. Clear-cell papillary renal cell  
5  
6 carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic  
7  
8 hybridization array study of seven cases. *Histopathology* 2011; 58(7):1064–71  
9
- 10  
11  
12 9. Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and  
13  
14 immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-  
15  
16 inducible factor pathway-related proteins. *Mod Pathol Off J U S Can Acad Pathol Inc* 2011;  
17  
18 24(9):1207–20  
19
- 20  
21  
22  
23 10. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in  
24  
25 end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on  
26  
27 histologic patterns distinct from those in sporadic adult renal neoplasia. *Am J Surg Pathol* 2006;  
28  
29 30(2):141–53  
30
- 31  
32  
33  
34 11. Liddell, H, Mare A, Hewood S, Bennett G, Chan HF. Clear cell papillary renal cell  
35  
36 carcinoma: A potential mimic of conventional clear cell renal carcinoma on core biopsy. *Case*  
37  
38 *Rep Uro* 2015; Epub 2015 Jan 29  
39
- 40  
41  
42 12. Silverman SG, Israel GM, Trinh QD. Incompletely characterized incidental renal masses:  
43  
44 emerging data support conservative management. *Radiology* 2015; 275(1):28-42  
45  
46
- 47  
48 13. Egbert ND, Caoili EM, Cohan RH, et al. Differentiation of papillary renal cell carcinoma  
49  
50 subtypes on CT and MRI. *AJR* 2013; 201(2):347–55  
51
- 52  
53  
54 14. Silverman SG, Akbar SA, Morteale KJ, Tuncali K, Bhagwat JG, Seifter JL. Multi-detector  
55  
56 row CT urography of normal urinary collecting system: furosemide versus saline as adjunct to  
57  
58 contrast medium. *Radiology* 2006; 240(3):749–55  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 15. Oliva MR, Glickman JN, Zou KH, et al. Renal cell carcinoma: t1 and t2 signal intensity  
5 characteristics of papillary and clear cell types correlated with pathology. AJR 2009;  
6  
7 192(6):1524–30  
8  
9
- 10  
11  
12 16. Shinagare AB, Vikram R, Jaffe C, et al. Radiogenomics of clear cell carcinoma: preliminary  
13 findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research  
14 Group. Abdom Imaging 2015; Epub 2015 Mar 10  
15  
16  
17
- 18  
19  
20 17. Israel GM, Silverman SG. The incidental renal mass. Radiol Clin North Am 2011;  
21  
22 49(2):369–83  
23  
24  
25
- 26  
27 18. Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass.  
28 Radiology 2008; 249(1):16–31  
29  
30  
31
- 32  
33 19. Chung EP, Herts BR, Linnell G, et al. Analysis of changes in attenuation of proven renal  
34 cysts on different scanning phases of triphasic MDCT. AJR 2004; 182(2):405–10  
35  
36  
37
- 38  
39 20. Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS. MRI features  
40 of renal oncocytoma and chromophobe renal cell carcinoma. AJR 2010;195:W421-W427  
41  
42  
43
- 44  
45 21. Sun M, Abdollah F, Bianchi M, et al. Treatment management of small renal masses in the  
46 21st century: a paradigm shift. Ann Surg Oncol 2012; 19(7):2380-2387  
47  
48  
49
- 50  
51 22. Lee-Felker SA, Felker ER, Tan N, et al. Qualitative and quantitative MDCT features for  
52 differentiating clear cell renal cell carcinoma from other solid renal cortical masses. AJR  
53  
54 2014;203(5):W516-W524  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 23. Young JR, Margolis D, Sauk S, Pantuck AJ, Savre J, Raman SS. Clear cell renal cell  
5 carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at  
6 multiphase multidetector CT. *Radiology* 2013; 267(2):444-53  
7  
8  
9  
10  
11  
12 24. Williamson SR, Eble JN, Cheng L, Grignon DJ. Clear cell papillary renal cell carcinoma:  
13 differential diagnosis and extended immunohistochemical profile. *Mod Pathol.* 2013; 26:697-708  
14  
15  
16  
17  
18 25. Ruppert-Kohlmayr AJ, Uggowitz M, Meissnitzer T, Ruppert G. Differentiation of renal  
19 clear cell carcinoma and renal papillary carcinoma using quantitative CT enhancement  
20 parameters. *AJR* 2004; 183:1387-1391  
21  
22  
23  
24  
25  
26 26. Zhang J, Lefkowitz RA, Ishill NM, et al. Solid renal cortical tumors: differentiation with CT.  
27 *Radiology* 2007; 244:494-504  
28  
29  
30  
31  
32 27. Sun M, Ngo L, Genega EM, et al. Renal cell carcinoma: dynamic contrast-enhanced MR  
33 imaging for differentiation of tumor subtypes-correlation with pathologic findings. *Radiology*  
34 2009; 250(3):793-802  
35  
36  
37  
38  
39  
40 28. Bata P, Gyebnar J, Laszlo D, et al. Clear cell renal cell carcinoma and papillary renal cell  
41 carcinoma: differentiation of distinct histological types with multiphase CT. *Diagn interv Radiol*  
42 2013; 19:387-392  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



**TABLE**

**Table 1: Imaging features of 54 patients with early stage clear cell tubulopapillary (CCTPRCC), clear cell (ccRCC) and papillary (pRCC) renal cell carcinoma**


<b>Imaging Feature</b>	<b>CCTPRCC (%)</b>	<b>ccRCC (%)</b>	<b>pRCC (%)</b>	<b>p value</b>
Maximum diameter (mm)	24	27	25	0.465
Side				
Right	11/18 (61)	11/18 (61)	12/18 (67)	0.924
Left	7/18 (39)	7/18 (39)	6/18 (33)	
Location				
Upper	5/18 (28)	9/18 (50)	5/18 (28)	0.274
Mid	7/18 (39)	3/18 (17)	9/18 (50)	
Lower	6/18 (33)	6/18 (33)	4/18 (22)	
Exophytic	16/18 (89)	17/18 (94)	18/18 (100)	0.416
Ill-defined margin	8/18 (44)	6/18 (33)	0/18 (0)	<b>0.003<sup>a</sup></b>
Calcification	3/18 (17)	0/18 (0)	0/18 (0)	0.054
Central scar	0/18 (0)	0/18 (0)	0/18 (0)	1.000
Capsule present	7/18 (39)	5/18 (28)	8/18 (44)	0.574
Solid	14/18 (78)	15/18 (83)	18/18 (100)	0.118
Nonenhancing areas	8/14 (57)	8/15 (53)	0/18 (0)	<b>0.0003<sup>a</sup></b>
Fat present	1/18 (6)	1/18 (6)	0/18 (0)	0.595
Nephrographic phase				
Homogeneous	2/18 (11)	4/18 (22)	8/18 (50)	0.033
Heterogeneous	16/18 (89)	14/18 (78)	8/18 (50)	
Mean unenhanced attenuation (HU)	24.9	25.9	33.7	<b>0.017<sup>a</sup></b>
Mean nephrographic attenuation (HU)	94.8	88.6	67.9	0.639
Mean excretory attenuation (HU)	66.6	60.7	55.6	0.317
Hemosiderin present	0/12 (0)	0/6 (0)	0/9 (0)	1.000

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


T1 unenhanced signal	3/12 (25)	2/6 (33)	7/9 (78)	0.045
Homogeneous	9/12 (75)	4/6 (67)	2/9 (22)	
Heterogeneous				
T1 unenhanced signal				
Hypointense	6/12 (50)	3/6 (50)	0/9 (0)	
Isointense	6/12 (50)	3/6 (50)	8/9 (89)	0.079
Hyperintense	0/12 (0)	0/6 (0)	1/9 (11)	
T2 signal				
Homogeneous	1/12 (8)	0/6 (0)	4/9 (44)	0.045
Heterogeneous	11/12 (92)	6/6 (100)	5/9 (56)	
T2 signal				
Hypointense	0/12 (0)	1/6 (17)	9/9 (100)	
Isointense	1/12 (8)	0/6 (0)	0/9 (0)	<b>0.0001<sup>a</sup></b>
Hyperintense	11/12 (92)	5/6 (83)	0/9 (0)	
DWI signal				
Homogeneous	0/4 (0)	0/4 (0)	2/2 (100)	0.007
Heterogeneous	4/4 (100)	4/4 (100)	0/2 (0)	
DWI signal				
Hypointense	0/4 (0)	1/4 (25)	0/2 (0)	
Isointense	0/4 (0)	0/4 (0)	0/2 (0)	0.435
Hyperintense	4/4 (100)	3/4 (75)	2/2 (100)	
Enhancement present on MRI	11/11 (100)	6/6 (100)	8/8 (100)	1.000
<sup>a</sup> Bold numbers denote statistically significant results				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


## FIGURES



**Fig. 1** – CCTPRCC (24.9 HU) demonstrated a lower mean unenhanced attenuation value than that of pRCC (33.7 HU) ( $p < 0.017$ ). **A**, 84-year-old woman with CCTPRCC (14 HU). **B**, 61-year-old woman with pRCC (51 HU).




**Fig. 2** – More CCTPRCCs were T2-hyperintense than pRCC ( $p < 0.0001$ ). **A**, 65-year-old man with CCTPRCC demonstrating heterogeneously hyperintense T2 signal. **B**, 52-year-old man with pRCC demonstrating homogeneously hypointense T2 signal.



17  
18  
19  
20  
21  
22  
23  
24  
25

**Fig. 3** – More CCTPRCCs had an ill-defined margin than pRCC ( $p=0.003$ ). **A**, 75-year-old woman with CCTPRCC demonstrating an ill-defined tumor margin. **B**, 64-year-old man with pRCC demonstrating a well-defined tumor margin.



39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Fig. 4** – Among the tumors which were classified as solid, CCTPRCC more frequently demonstrated nonenhancing areas than pRCC ( $p=0.0003$ ). **A**, 76-year-old man with CCTPRCC demonstrating an eccentric nonenhancing area within the tumor. **B**, 69-year-old woman with pRCC demonstrating no nonenhancing areas.